Participants: ≥50yo, primary or recurrent subfoveal CNV (predominantly classic, minimally classic, or occult with no classic) from AMD, BCV 20/40-20/320
Intervention:
Group 1: sham injection
Group 2: Intravitreal ranibizumab 0.3mg
Group 3: Intravitreal ranibizumab 0.5mg
Source Archive